Genprex (STU:2DE0) YoY EBITDA Growth : 50.91% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genprex YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Genprex's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 50.91%.

Genprex's EBITDA per Share for the three months ended in Jun. 2024 was €-2.80.

Genprex YoY EBITDA Growth Historical Data

The historical data trend for Genprex's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex YoY EBITDA Growth Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

23.97

30.66

6.51

-20.72

-11.09

Genprex Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
YoY EBITDA Growth	Get a 7-Day Free Trial															-25.20	2.72	28.60	51.27	50.91

Genprex YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Genprex's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-20.821	-	-18.742)	/	\| -18.742 \|
=	-11.09 %

Genprex's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

	YoY EBITDA Growth (Q: Jun. 2024 )
=	(EBITDA per Share (Q: Jun. 2024 )	-	EBITDA per Share (Q: Jun. 2023 ))	/	\| EBITDA per Share (Q: Jun. 2023 )) \|
=	(-2.8	-	-5.704)	/	\| -5.704 \|
=	50.91 %

Genprex YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Genprex's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Genprex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (STU:2DE0) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

GNPX:USA 0A8I:UK

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Headlines

No Headlines